NexImmune, Inc. (NEXI)
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Medical - Pharmaceuticals
Industry: Medical - Pharmaceuticals
NexImmune, Inc.
OTC:NEXIHealthcare · Biotechnology
$0.0001
Mkt Cap$139
Float1.18M
O/S1.39M
Inst Own0.8%
SI<0.1%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$32.34M
Total Assets$8.59M
Free Cash Flow-$31.48M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$69K
Total Equity$3.51M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:25Reverse splitOct 19, 202325 shares → 1
Balance Sheet Details
Assets$8.59M
Liabilities$5.08M
Accounts Receivable$0
Accounts Payable$1.34M
Inventory$0
PP&E (Net)$1.4M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $1.02M | $1.5M | $870K | $619K | $436K | $205K |
| Gross Profit | -$1.02M | -$1.5M | -$870K | -$619K | -$436K | -$205K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $18.26M | $47.15M | $37.46M | $17.84M | $15.17M | $8M |
| Selling, General, and Administrative | $9.91M | $15.93M | $15.8M | $10.01M | $5.71M | $5.24M |
| Other | $691K | -$1.5M | -$870K | -$619K | $0 | $137K |
| Total Operating Expenses | $28.17M | $61.59M | $52.39M | $27.23M | $20.89M | $13.24M |
| Operating Income (EBIT) | -$29.19M | -$63.08M | -$53.26M | -$27.85M | -$20.89M | -$13.24M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $905K | $1.68M | $0 | $0 |
| Interest Income | $698K | $664K | $53K | $21K | $247K | $272K |
| Other Income (Expense) | -$3.15M | $577K | $2.35M | -$2.01M | $339K | $409K |
| Income Before Tax (EBT) | -$32.34M | -$62.51M | -$50.9M | -$29.87M | -$20.55M | -$12.83M |
| Income Tax Expense | $0 | -$576.69M | $844K | $1.77M | -$247K | $0 |
| Net Income | -$32.34M | $514.18M | -$51.75M | -$31.64M | -$20.3M | -$12.83M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -30.82 | 534.29 | -56.67 | -34.76 | -22.53 | -14.25 |
| Diluted EPS | -30.82 | 534.29 | -56.67 | -34.76 | -22.53 | -14.25 |
| Weighted Average OS | 1.05M | 962,364 | 913,156 | 910,311 | 900,861 | 900,861 |
| EBITDA | -$28.17M | -$61.51M | -$49.13M | -$27.56M | -$20.45M | -$13.04M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $3.2M | $34.64M | $30.33M | $5.03M | $9.13M | $426K |
| Short-Term Investments | $1.44M | $0 | $51.49M | $1.01B | $1.01M | $11.63M |
| Cash and Short-Term Investments | $4.65M | $34.64M | $81.82M | $5.1M | $10.14M | $12.06M |
| Accounts Receivable | $0 | $74K | $0 | $0 | $6K | $74K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $235K | $457K | $167K | $1.03M | $68K | $0 |
| Total Current Assets | $5.4M | $37.37M | $86.28M | $8.39M | $11.04M | $12.33M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $1.4M | $5.43M | $4.43M | $2.89M | $2.58M | $1.7M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.79M | $265K | $324K | $23K | $104K | $114K |
| Total Long-Term Assets | $3.19M | $5.69M | $4.75M | $2.91M | $2.68M | $1.81M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $8.59M | $43.06M | $91.03M | $11.3M | $13.72M | $14.14M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $1.34M | $2.38M | $1.05M | $2.76M | $1.17M | $861K |
| Short-Term Debt | $0 | $0 | $0 | $19.12M | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $2.6M | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | -$30K | $208K | $371K |
| Total Current Liabilities | $5.08M | $10.33M | $7.22M | $27.03M | $3.03M | $3M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $56K | $28K | $82K | $329K |
| Total Long-Term Liabilities | $0 | $426K | $56K | $28K | $82K | $329K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.08M | $10.76M | $7.27M | $27.06M | $3.11M | $3.33M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $91.03B | $53.62M | $53.62M | $35.05M |
| Common Stock | $3K | $3K | $2K | $126 | $126 | $117 |
| Retained Earnings | -$222.59M | -$190.25M | -$127.74M | -$77.58M | -$47.72M | -$27.17M |
| Comprehensive Income & Other | $0 | $0 | $3K | $0 | $506 | -$30K |
| Other Stockholders' Equity | $226.1M | $222.55M | $211.5M | $61.83M | $58.33M | $37.98M |
| Total Equity | $3.51M | $32.3M | $83.76M | -$15.75M | $10.61M | $10.81M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $8.59M | $43.06M | $91.03M | $11.3M | $13.72M | $14.14M |
| Supplementary Data | ||||||
| Total Debt | $69K | $1.02M | $0 | $19.12M | $0 | $35.05M |
| Net Debt | -$3.13M | -$33.62M | -$30.33M | $14.09M | -$9.13M | $34.62M |
Cash Flow Statement
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||
| Net Income | -$32.34M | -$62.51M | -$50.9M | -$29.87M | -$20.55M | -$12.83M |
| Depreciation & Amortization | $1.02M | $995K | $870K | $619K | $436K | $205K |
| Deferred Income Tax | $0 | $0 | -$3.29M | $442K | $0 | $0 |
| Stock-Based Compensation | $3.55M | $5.87M | $5.98M | $1.22M | $1.53M | $1.21M |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.04M | $1.39M | -$1M | $702K | $235K | $192K |
| Other Working Capital | -$3.84M | $2.54M | $1.66M | -$792K | -$1.08M | $112K |
| Total Working Capital Change | -$4.88M | $3.93M | $655K | -$89K | -$842K | $304K |
| Other Non-Cash Items | $1.21M | $521K | $904K | $1.27M | $2K | $1.42M |
| Net Cash from Operating | -$31.43M | -$51.19M | -$45.79M | -$26.4M | -$19.42M | -$11.12M |
| Investing Activities | ||||||
| Capital Expenditures | -$49K | -$1.26M | -$2.35M | -$865K | -$1.25M | -$938K |
| Acquisitions | $0 | $81K | -$32.06M | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$21.51M | -$90.46M | $0 | -$7.07M | -$17.61M |
| Sales of Investments | $0 | $73M | $39M | $1.01M | $17.73M | $5.95M |
| Other Investing Activities | $4K | $0 | $32.06M | $80K | $10K | -$40K |
| Net Cash from Investing | -$44K | $50.32M | -$53.81M | $222K | $9.42M | -$12.64M |
| Financing Activities | ||||||
| Debt Repaid | - | - | -$9.02M | -$22.44M | $18K | $7K |
| Common Stock Issuance | $0 | $5.15M | $114.72M | $7K | $18.78M | $9.19M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $33K | $1.15M | -$364K | $210K | $5K |
| Net Cash from Financing | $0 | $5.18M | $124.89M | $22.08M | $18.76M | $9.18M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$31.47M | $4.3M | $25.3M | -$4.1M | $8.77M | -$14.58M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$31.43M | -$51.19M | -$45.79M | -$26.4M | -$19.42M | -$11.12M |
| Capital Expenditure | -$49K | -$1.26M | -$2.35M | -$865K | -$1.25M | -$938K |
| Free Cash Flow | -$31.48M | -$52.45M | -$48.14M | -$27.27M | -$20.66M | -$12.06M |
| Cash at Beginning | $34.7M | $30.39M | $5.1M | $9.2M | $426K | $15.01M |
| Cash at End | $3.22M | $34.7M | $30.39M | $5.1M | $9.2M | $426K |